Risks from deferring treatment for genitourinary cancers: a collaborative review to aid triage and management during the COVID-19 pandemic
Context The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the
treatment of many urologic cancers. Objective To provide a contemporary picture of the risks …
treatment of many urologic cancers. Objective To provide a contemporary picture of the risks …
Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients
HJ Boyle, S Alibhai, L Decoster, E Efstathiou… - European Journal of …, 2019 - Elsevier
Background The median age of prostate cancer diagnosis is 66 years, and the median age
of men who die of the disease is eighty years. The public health impact of prostate cancer is …
of men who die of the disease is eighty years. The public health impact of prostate cancer is …
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival …
K Fizazi, NP Tran, L Fein, N Matsubara… - The Lancet …, 2019 - thelancet.com
Background In the interim analyses of the LATITUDE study, the addition of abiraterone
acetate plus prednisone to androgen deprivation therapy (ADT) led to a significant …
acetate plus prednisone to androgen deprivation therapy (ADT) led to a significant …
Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis
Context There have been substantial changes in the management of men with metastatic
hormone-sensitive prostate cancer (mHSPC) over the past 5 yr, with upfront combination …
hormone-sensitive prostate cancer (mHSPC) over the past 5 yr, with upfront combination …
Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting
K Ng, S Smith, J Shamash - Oncology and therapy, 2020 - Springer
The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has
changed radically in recent years. Androgen deprivation therapy (ADT) alone was for …
changed radically in recent years. Androgen deprivation therapy (ADT) alone was for …
[HTML][HTML] Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive …
S Feyerabend, F Saad, T Li, T Ito, J Diels… - European journal of …, 2018 - Elsevier
Aim Androgen deprivation therapy (ADT) has long been the gold standard for patients with
metastatic hormone-sensitive prostate cancer (mHSPC). Clinical trials have demonstrated …
metastatic hormone-sensitive prostate cancer (mHSPC). Clinical trials have demonstrated …
Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta …
Context Novel prospective randomized controlled observations addressing combination
therapy in metastatic hormone-sensitive prostate cancer (mHSPC) have demonstrated …
therapy in metastatic hormone-sensitive prostate cancer (mHSPC) have demonstrated …
Real-world cardiovascular outcomes associated with degarelix vs leuprolide for prostate cancer treatment
JD Wallach, Y Deng, RG McCoy, SS Dhruva… - JAMA network …, 2021 - jamanetwork.com
Importance With a growing interest in the use of real-world evidence for regulatory decision-
making, it is important to understand whether real-world data can be used to emulate the …
making, it is important to understand whether real-world data can be used to emulate the …
Management of patients with metastatic castration-sensitive prostate cancer in the real-world setting in the United States
CJ Ryan, X Ke, MH Lafeuille, H Romdhani… - The Journal of …, 2021 - auajournals.org
Purpose: This study provides a contemporary assessment of the treatment patterns, health
care resource utilization (HRU) and costs among metastatic castration-sensitive prostate …
care resource utilization (HRU) and costs among metastatic castration-sensitive prostate …
[HTML][HTML] What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis
Abstract Background Our prior Systemic Treatment Options for Cancer of the Prostate
systematic reviews showed improved survival for men with metastatic hormone-naive …
systematic reviews showed improved survival for men with metastatic hormone-naive …